It has not been well known about the changes of bone metabolic markers, bone mineral density and other bone-related markers after teriparatide and/or denosumab treatment in Japanese osteoporotic patients.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
100
To examine the effectiveness of denosumab in osteoporotic patients
To examine the effectiveness of teriparatide in osteoporotic patients
To examine the effectiveness of denosumab and teriparatide in osteoporotic patients
Yukio Nakamura
Matsumoto, Nagano, Japan
RECRUITINGChanges of bone mineral density
Bone mineral density will be examined every 4-6 months to evaluate the suitability of the drug.
Time frame: every 4-6 months
Changes of bone turnover markers
Bone turnover markers will be examined every 3-6 months to evaluate the suitability of the drug.
Time frame: every 3-6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.